Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Elderly Patients

Summary

This study was undertaken to determine the effect of age on the pharmacokinetics of cefotaxime and desacetylcefotaxime after intravenous administration of 1g cefotaxime. 30 elderly patients suffering from acute infection were enrolled in the study. They were divided into 3 subgroups (group I aged 60 to 70 years, group II aged 71 to 80 years, group III aged over 80 years) with 5 men and 5 women in each. The elimination of cefotaxime in patients aged between 60 and 80 years was slightly slower than that in young people: elimination half lives (in men and women, respectively) in group I were 1.2 and 1.58 hours, in group II, 1.45 and 1.57 hours and in group III, 2.56 and 2.59 hours. The change in elimination of desacetylcefotaxime was similar to that of cefotaxime, but less marked. The slower elimination of cefotaxime in patients over 80 years of age may allow reduction in the dose without jeopardising the efficacy of therapy, whereas in patients under 80 years of age the normal dosage is required.